<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS Comput Biol</journal-id><journal-id journal-id-type="iso-abbrev">PLoS Comput. Biol</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">ploscomp</journal-id><journal-title-group><journal-title>PLoS Computational Biology</journal-title></journal-title-group><issn pub-type="ppub">1553-734X</issn><issn pub-type="epub">1553-7358</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5714397</article-id><article-id pub-id-type="pmid">29155812</article-id><article-id pub-id-type="publisher-id">PCOMPBIOL-D-17-00810</article-id><article-id pub-id-type="doi">10.1371/journal.pcbi.1005838</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Vaccination and Immunization</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Vaccination and Immunization</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Public and Occupational Health</subject><subj-group><subject>Preventive Medicine</subject><subj-group><subject>Vaccination and Immunization</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Infectious Diseases</subject><subj-group><subject>Viral Diseases</subject><subj-group><subject>Influenza</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>People and Places</subject><subj-group><subject>Population Groupings</subject><subj-group><subject>Age Groups</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Infectious Diseases</subject><subj-group><subject>Infectious Disease Control</subject><subj-group><subject>Vaccines</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Social Sciences</subject><subj-group><subject>Economics</subject><subj-group><subject>Economic Analysis</subject><subj-group><subject>Cost-Effectiveness Analysis</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Epidemiology</subject></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Public and Occupational Health</subject></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Population Biology</subject><subj-group><subject>Population Metrics</subject><subj-group><subject>Death Rates</subject></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>fluEvidenceSynthesis: An R package for evidence synthesis based analysis of epidemiological outbreaks</article-title><alt-title alt-title-type="running-head">fluEvidenceSynthesis: An R package for epidemiological outbreaks</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-2383-5305</contrib-id><name><surname>van Leeuwen</surname><given-names>Edwin</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Software</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Visualization</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-4132-3933</contrib-id><name><surname>Klepac</surname><given-names>Petra</given-names></name><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Thorrington</surname><given-names>Dominic</given-names></name><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Pebody</surname><given-names>Richard</given-names></name><role content-type="http://credit.casrai.org/">Funding acquisition</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Baguelin</surname><given-names>Marc</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Software</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib></contrib-group><aff id="aff001">
<label>1</label>
<addr-line>Respiratory Diseases Department, Public Health England, London, United Kingdom</addr-line>
</aff><aff id="aff002">
<label>2</label>
<addr-line>National Heart and Lung Institute, Imperial College London, London, United Kingdom</addr-line>
</aff><aff id="aff003">
<label>3</label>
<addr-line>School of Public Health, Imperial College London, London, United Kingdom</addr-line>
</aff><aff id="aff004">
<label>4</label>
<addr-line>London School of Hygiene and Tropical Medicine, London, United Kingdom</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Schneidman</surname><given-names>Dina</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">
<addr-line>Hebrew University of Jerusalem, ISRAEL</addr-line>
</aff><author-notes><fn fn-type="COI-statement" id="coi001"><p>The authors have declared that no competing interests exist.</p></fn><corresp id="cor001">* E-mail: <email>edwinvanl@gmail.com</email></corresp></author-notes><pub-date pub-type="collection"><month>11</month><year>2017</year></pub-date><pub-date pub-type="epub"><day>20</day><month>11</month><year>2017</year></pub-date><volume>13</volume><issue>11</issue><elocation-id>e1005838</elocation-id><history><date date-type="received"><day>19</day><month>5</month><year>2017</year></date><date date-type="accepted"><day>20</day><month>10</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; 2017 van Leeuwen et al</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>van Leeuwen et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pcbi.1005838.pdf"/><abstract><p>Public health related decisions often have to balance the cost of intervention strategies with the benefit of the reduction in disease burden. While the cost can often be inferred, forward modelling of the effect of different intervention options is complicated and disease specific. Here we introduce a package that is aimed to simplify this process. The package allows one to infer parameters using a Bayesian approach, perform forward modelling of the likely results of the proposed intervention and finally perform cost effectiveness analysis of the results. The package is based on a method previously used in the United Kingdom to inform vaccination strategies for influenza, with extensions to make it easily adaptable to other diseases and data sources.</p></abstract><funding-group><award-group id="award001"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100000272</institution-id><institution>National Institute for Health Research</institution></institution-wrap></funding-source><award-id>HPRU</award-id><principal-award-recipient><name><surname>van Leeuwen</surname><given-names>Edwin</given-names></name></principal-award-recipient></award-group><award-group id="award002"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100000272</institution-id><institution>National Institute for Health Research</institution></institution-wrap></funding-source><award-id>HPRU</award-id><principal-award-recipient><name><surname>Baguelin</surname><given-names>Marc</given-names></name></principal-award-recipient></award-group><award-group id="award003"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100000272</institution-id><institution>National Institute for Health Research</institution></institution-wrap></funding-source><award-id>HPRU</award-id><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-4132-3933</contrib-id><name><surname>Klepac</surname><given-names>Petra</given-names></name></principal-award-recipient></award-group><award-group id="award004"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100000265</institution-id><institution>Medical Research Council</institution></institution-wrap></funding-source><award-id>MR/J008761/1</award-id><principal-award-recipient><name><surname>van Leeuwen</surname><given-names>Edwin</given-names></name></principal-award-recipient></award-group><award-group id="award005"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100007601</institution-id><institution>Horizon 2020</institution></institution-wrap></funding-source><award-id>634446</award-id><principal-award-recipient><name><surname>Thorrington</surname><given-names>Dominic</given-names></name></principal-award-recipient></award-group><funding-statement>EvL, PK and MB were funded by the National Institute for Health Research (NIHR) Health Protection Research Units (HPRU) in Respiratory Infections (EvL, Imperial College London), Modelling Methodology (PK, Imperial College London) and Immunisation (MB, London School of Hygiene and Tropical Medicine) in partnership with Public Health England (PHE). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, the Department of Health or Public Health England <ext-link ext-link-type="uri" xlink:href="http://www.nihr.ac.uk/about-us/how-we-are-managed/our-structure/research/health-protection-research-units.htm">http://www.nihr.ac.uk/about-us/how-we-are-managed/our-structure/research/health-protection-research-units.htm</ext-link>. EvL also acknowledges funding from the UK Medical Research Council (Project MR/J008761/1): <ext-link ext-link-type="uri" xlink:href="https://www.mrc.ac.uk">https://www.mrc.ac.uk</ext-link>. DT was funded by the I-MOVE+ (Integrated Monitoring of Vaccines in Europe) project that received funding from the European Union&#x02019;s Horizon 2020 research and innovation programme under grant agreement #634446: <ext-link ext-link-type="uri" xlink:href="https://ec.europa.eu/programmes/horizon2020/">https://ec.europa.eu/programmes/horizon2020/</ext-link>. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="4"/><table-count count="0"/><page-count count="12"/></counts><custom-meta-group><custom-meta><meta-name>PLOS Publication Stage</meta-name><meta-value>vor-update-to-uncorrected-proof</meta-value></custom-meta><custom-meta><meta-name>Publication Update</meta-name><meta-value>2017-12-04</meta-value></custom-meta><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are included in the R package, which is publicly available from github: <ext-link ext-link-type="uri" xlink:href="https://github.com/MJomaba/flu-evidence-synthesis">https://github.com/MJomaba/flu-evidence-synthesis</ext-link>.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are included in the R package, which is publicly available from github: <ext-link ext-link-type="uri" xlink:href="https://github.com/MJomaba/flu-evidence-synthesis">https://github.com/MJomaba/flu-evidence-synthesis</ext-link>.</p></notes></front><body><disp-quote><p>This is a <italic>PLOS Computational Biology</italic> Software paper.</p></disp-quote><sec sec-type="intro" id="sec001"><title>Introduction</title><p>In-depth cost effectiveness analysis of disease intervention strategies has been difficult to perform due to a variety of reasons, including the inherent complexity of disease dynamics, lack of data and difficulty in predicting the success of the proposed interventions. Currently available tools for analysing epidemiological data mainly focus on statistical analyses and simple regression models [<xref rid="pcbi.1005838.ref001" ref-type="bibr">1</xref>&#x02013;<xref rid="pcbi.1005838.ref003" ref-type="bibr">3</xref>], which is not sufficient to model the population wide effects of proposed interventions, which include both direct and indirect effects. The exception here is amei, an R package for optimising vaccination strategies in using an adaptive management framework while evaluating costs of an underlying stochastic epidemiological model [<xref rid="pcbi.1005838.ref004" ref-type="bibr">4</xref>], but this package mainly relies on the use of a single (high quality) source of information. Synthesising information from different sources of data and performing a detailed cost effectiveness analysis of control strategies is not supported by the currently available packages.</p><p>In an effort to fill this gap and make sophisticated cost effectiveness analysis methods more accessible and standardised we have developed an R package that simplifies the process. Focusing on influenza, we present a package that offers detailed cost effectiveness analyses of intervention strategies in a Bayesian inference framework that applies evidence synthesis techniques to combine the available evidence from multiple data sources that can be stratified by age and risk status and combined with age-stratified mixing patterns. The implementation is based on a Susceptible Exposed Infectious Removed (SEIR) model previously developed for pandemic influenza [<xref rid="pcbi.1005838.ref005" ref-type="bibr">5</xref>] and later used for assessing the cost/benefit of changes in the seasonal influenza vaccine programme in the United Kingdom, and adapted to make it more generally applicable to other settings [<xref rid="pcbi.1005838.ref006" ref-type="bibr">6</xref>, <xref rid="pcbi.1005838.ref007" ref-type="bibr">7</xref>].</p><p>The package is particularly suitable for modelling and evaluating intervention strategies for directly transmissible diseases that use proxy data for incidence, such as influenza-like-illness (ILI) counts for influenza and respiratory syncytial virus (RSV). The package deals with the whole pipeline, starting from re-organising users&#x02019; different data sources to standardise their format to be compatible with the package, to modelling, Bayesian inference, analysing vaccination scenarios and cost effectiveness. Crucially, it includes a number of high level functions that can do a particular analysis, and also provides access to the low level functions that are needed if the user wants to adapt the analysis and tailor it to their specific needs (e.g. user-provided data may be different than the data we have accessible).</p></sec><sec id="sec002"><title>Design and implementation</title><p><xref ref-type="fig" rid="pcbi.1005838.g001">Fig 1</xref> illustrates the general workflow of the package. The package takes data on the influenza outbreak and related data, such as contact rates and demographic structure, as its input, which can then be organised into different age and risk groups. Given a set of parameters and considering the underlying model, we calculate the likelihood of observing these data. Given the data and the likelihood function, the package uses an adaptive MCMC algorithm to derive the posterior distribution of parameter values of the underlying epidemiological model. These posterior parameter values can be used to explore alternative intervention strategies, and for the cost-benefit analysis by using the functionalities of the forward modelling.</p><fig id="pcbi.1005838.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1005838.g001</object-id><label>Fig 1</label><caption><title>Workflow for the fluEvidenceSynthesis package.</title></caption><graphic xlink:href="pcbi.1005838.g001"/></fig><sec id="sec003"><title>Data representation</title><p>Data analysed in the package need to be transformed into a standardised format. The default input is in form of weekly data with each row representing the data for that week. Other dates can be used when using the lower level functions provided by the package. Columns contain the data stratified by age group. If the data are also stratified by risk group then the first group of columns will hold the data for one risk group, stratified by age group. The next set of columns will be the next risk group by age group, etc. The input as used in the examples consist of (see <xref ref-type="fig" rid="pcbi.1005838.g001">Fig 1</xref>):</p><list list-type="bullet"><list-item><p>Weekly ILI counts, stratified by age in separate columns.</p></list-item><list-item><p>Weekly virological data, stratified by age in separate columns.</p></list-item><list-item><p>Weekly vaccination data, stratified by risk group and by age as explained above.</p></list-item><list-item><p>Population size by age.</p></list-item><list-item><p>Contact data by age group. The example data included in the package are based on the POLYMOD study [<xref rid="pcbi.1005838.ref008" ref-type="bibr">8</xref>].</p></list-item></list></sec><sec id="sec004"><title>Functionalities</title><sec id="sec005"><title>Stratifying the data</title><p>General functions are provided as part of the package to stratify the data and convert them to a suitable formatting for model fitting (e.g <monospace>stratify_by_age(&#x02026;)</monospace>) and easily stratify the data into different user-specified age and risk groups. The choice of age groups and risk groups is flexible and depends on the data provided and the goal of the user. For example, for the UK the influenza occurrence data are separated into 5 age groups, while the vaccination data are divided into 7 different age groups, so it was decided to model 7 different age groups, but transform them into 5 before performing the fitting [<xref rid="pcbi.1005838.ref006" ref-type="bibr">6</xref>].</p></sec><sec id="sec006"><title>Vaccination scenarios</title><p>The package defines vaccination scenarios as a combination of the effectiveness of the vaccine against the dominant strain and the coverage over time. The effectiveness of the influenza vaccine is highly dependent on the match between the vaccine strain and the dominant strain circulating in the population. Influenza vaccine effectiveness is also age dependent, with the vaccine generally being less effective for the older age groups (e.g. because of immunosenescence). Vaccine coverage is determined by the vaccination programme. In most countries influenza vaccination is aimed at individuals aged 65 years and above, and at the high risk groups. In the United States and, more recently, in the UK the seasonal influenza vaccination programme was extended to include healthy children [<xref rid="pcbi.1005838.ref007" ref-type="bibr">7</xref>, <xref rid="pcbi.1005838.ref009" ref-type="bibr">9</xref>]. The period during which the vaccination programme is carried out is also country-dependent. In the UK vaccination starts in October and runs until the end of January, with the largest uptake rate during the first month. The function <monospace>as.vaccination.calendar(&#x02026;)</monospace> takes the effectiveness and coverage by age and risk groups and the dates at which the coverage data were measured to construct a calendar as used in the epidemiological model.</p></sec><sec id="sec007"><title>Epidemiological model</title><p>The epidemiological model implemented in the package is an SEIR model, with two compartments for the Exposed and Infectious states that result in a more realistic gamma distributed average time for both the Exposed and Infectious states (rather than an exponentially distributed waiting time with single <italic>E</italic> and <italic>I</italic> compartments). The general model has the following form:
<disp-formula id="pcbi.1005838.e001"><alternatives><graphic xlink:href="pcbi.1005838.e001.jpg" id="pcbi.1005838.e001g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M1"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac></mml:mtd><mml:mtd columnalign="center"><mml:mrow><mml:mo>=</mml:mo></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mo>-</mml:mo><mml:msub><mml:mo>&#x003bb;</mml:mo><mml:mi>i</mml:mi></mml:msub><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="right"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>k</mml:mi></mml:mrow><mml:mn>1</mml:mn></mml:msubsup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac></mml:mtd><mml:mtd columnalign="center"><mml:mrow><mml:mo>=</mml:mo></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:msub><mml:mo>&#x003bb;</mml:mo><mml:mi>i</mml:mi></mml:msub><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mi>&#x003b3;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>k</mml:mi></mml:mrow><mml:mn>1</mml:mn></mml:msubsup></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="right"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>k</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac></mml:mtd><mml:mtd columnalign="center"><mml:mrow><mml:mo>=</mml:mo></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:msub><mml:mi>&#x003b3;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mspace width="1pt"/><mml:mo>(</mml:mo><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>k</mml:mi></mml:mrow><mml:mn>1</mml:mn></mml:msubsup><mml:mo>-</mml:mo><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>k</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="right"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>k</mml:mi></mml:mrow><mml:mn>1</mml:mn></mml:msubsup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac></mml:mtd><mml:mtd columnalign="center"><mml:mrow><mml:mo>=</mml:mo></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:msub><mml:mi>&#x003b3;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>k</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup><mml:mo>-</mml:mo><mml:msub><mml:mi>&#x003b3;</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>k</mml:mi></mml:mrow><mml:mn>1</mml:mn></mml:msubsup></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="right"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>k</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac></mml:mtd><mml:mtd columnalign="center"><mml:mrow><mml:mo>=</mml:mo></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:msub><mml:mi>&#x003b3;</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mspace width="1pt"/><mml:mo>(</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>k</mml:mi></mml:mrow><mml:mn>1</mml:mn></mml:msubsup><mml:mo>-</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>k</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="right"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac></mml:mtd><mml:mtd columnalign="center"><mml:mrow><mml:mo>=</mml:mo></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:msub><mml:mi>&#x003b3;</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>k</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(1)</label></disp-formula>
where <italic>S</italic><sub><italic>ik</italic></sub> is the number of susceptibles in the age group <italic>i</italic> and risk group <italic>k</italic>, <inline-formula id="pcbi.1005838.e002"><alternatives><graphic xlink:href="pcbi.1005838.e002.jpg" id="pcbi.1005838.e002g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M2"><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>k</mml:mi></mml:mrow><mml:mn>1</mml:mn></mml:msubsup></mml:math></alternatives></inline-formula> and <inline-formula id="pcbi.1005838.e003"><alternatives><graphic xlink:href="pcbi.1005838.e003.jpg" id="pcbi.1005838.e003g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M3"><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>k</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:math></alternatives></inline-formula> are two compartments with exposed but not yet infectious individuals of age group <italic>i</italic> and risk group <italic>k</italic>, <inline-formula id="pcbi.1005838.e004"><alternatives><graphic xlink:href="pcbi.1005838.e004.jpg" id="pcbi.1005838.e004g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M4"><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>k</mml:mi></mml:mrow><mml:mn>1</mml:mn></mml:msubsup></mml:math></alternatives></inline-formula> and <inline-formula id="pcbi.1005838.e005"><alternatives><graphic xlink:href="pcbi.1005838.e005.jpg" id="pcbi.1005838.e005g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M5"><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>k</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:math></alternatives></inline-formula> represent infectious individuals, and immune individuals of age group <italic>i</italic> and risk group <italic>k</italic> are given by <italic>R</italic><sub><italic>ik</italic></sub>. The overall rate of loss of latency and infectiousness are respectively given by <italic>&#x003b3;</italic><sub>1</sub>/2 and <italic>&#x003b3;</italic><sub>2</sub>/2, while the age-group-specific force of infection &#x003bb;<sub><italic>i</italic></sub> is given by
<disp-formula id="pcbi.1005838.e006"><alternatives><graphic xlink:href="pcbi.1005838.e006.jpg" id="pcbi.1005838.e006g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M6"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:msub><mml:mo>&#x003bb;</mml:mo><mml:mi>i</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>&#x003c3;</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mspace width="1pt"/><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>x</mml:mi></mml:munderover><mml:mspace width="1pt"/><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>y</mml:mi></mml:munderover><mml:mspace width="1pt"/><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mspace width="1pt"/><mml:mo>(</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>j</mml:mi><mml:mi>k</mml:mi></mml:mrow><mml:mn>1</mml:mn></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>j</mml:mi><mml:mi>k</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(2)</label></disp-formula>
where <italic>&#x003b2;</italic><sub><italic>i</italic>,<italic>j</italic></sub> is the effective contact rate between individuals in age group <italic>i</italic> and age group <italic>j</italic>, and <italic>&#x003c3;</italic><sub><italic>i</italic></sub> is the susceptibility of the age group <italic>i</italic> (that can be inferred from serological data) and <italic>x</italic> and <italic>y</italic> are the total number of age groups and risk groups, respectively. The effective contact rate is the transmission rate (&#x0039b;) multiplied with the probability of a contact between a individual in age group <italic>i</italic> and one in age group <italic>j</italic> (<italic>C</italic><sub><italic>i</italic>,<italic>j</italic></sub>).</p><p><xref ref-type="disp-formula" rid="pcbi.1005838.e001">Eq 1</xref> defines the trajectory of the infection for each age and risk group. To implement vaccination in the package we further separate each of the epidemiological compartments (SEEIIR) in the model (<xref ref-type="disp-formula" rid="pcbi.1005838.e001">1</xref>) into vaccinated and non-vaccinated groups. Non-vaccinated people of age <italic>i</italic> and risk <italic>k</italic> are vaccinated at a given rate (<italic>&#x003bc;</italic><sub><italic>ik</italic></sub>) regardless of their epidemiological status. If the subject has already been exposed or infected, the infection progresses as normal. Depending on the efficacy of the vaccine (<italic>&#x003b1;</italic><sub><italic>i</italic></sub>), a proportion of vaccinated susceptibles will become immune (<italic>&#x003bc;</italic><sub><italic>ik</italic></sub><italic>&#x003b1;</italic><sub><italic>i</italic></sub><italic>S</italic><sub><italic>ik</italic></sub>) and the total daily rate with which susceptible individuals become vaccinated and recovered is <italic>&#x003bc;</italic><sub><italic>ik</italic></sub>(<italic>R</italic><sub><italic>ik</italic></sub> + <italic>&#x003b1;</italic><sub><italic>i</italic></sub><italic>S</italic><sub><italic>ik</italic></sub>). If the vaccine is not 100% effective a proportion of vaccinated individuals will become &#x02018;vaccinated susceptibles&#x02019; (<italic>&#x003bc;</italic><sub><italic>ik</italic></sub>(1 &#x02212; <italic>&#x003b1;</italic><sub><italic>i</italic></sub>)<italic>S</italic><sub><italic>ik</italic></sub>). For full details of the underlying model see the supplementary information of [<xref rid="pcbi.1005838.ref006" ref-type="bibr">6</xref>].</p></sec><sec id="sec008"><title>Inference</title><p>In addition to the numerically optimised epidemiological model we also implemented a highly optimised likelihood function. The basic likelihood function incorporated in the package has the following form for each age group (<italic>i</italic>):
<disp-formula id="pcbi.1005838.e007"><alternatives><graphic xlink:href="pcbi.1005838.e007.jpg" id="pcbi.1005838.e007g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M7"><mml:mrow><mml:mi mathvariant="script">L</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:msubsup><mml:mi>n</mml:mi><mml:mi>i</mml:mi><mml:mo>+</mml:mo></mml:msubsup><mml:mo>,</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>m</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>|</mml:mo><mml:msub><mml:mi>&#x003f5;</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:mi>&#x003c8;</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mi>&#x003b8;</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:munder><mml:mo>&#x02211;</mml:mo><mml:msubsup><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mo>+</mml:mo></mml:msubsup></mml:munder><mml:mspace width="1pt"/><mml:mi mathvariant="script">L</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:msubsup><mml:mi>n</mml:mi><mml:mi>i</mml:mi><mml:mo>+</mml:mo></mml:msubsup><mml:mo>,</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>m</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>|</mml:mo><mml:msubsup><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mo>+</mml:mo></mml:msubsup><mml:mo>,</mml:mo><mml:msub><mml:mi>&#x003b8;</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mi mathvariant="script">L</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:msubsup><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mo>+</mml:mo></mml:msubsup><mml:mo>,</mml:mo><mml:msub><mml:mi>m</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>|</mml:mo><mml:msub><mml:mi>&#x003f5;</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:mi>&#x003c8;</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mi>&#x003b8;</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></disp-formula>
The likelihood of the data, given the ODE model, is separated into two parts. First, we assume that the virologically tested sera (<italic>n</italic><sub><italic>i</italic></sub>) are a subsample of the people identified with an influenza-like-illness. As such, the number tested positive (<inline-formula id="pcbi.1005838.e008"><alternatives><graphic xlink:href="pcbi.1005838.e008.jpg" id="pcbi.1005838.e008g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M8"><mml:msubsup><mml:mi>n</mml:mi><mml:mi>i</mml:mi><mml:mo>+</mml:mo></mml:msubsup></mml:math></alternatives></inline-formula>) is distributed as a hypergeometric function, with the number of people tested (<italic>n</italic><sub><italic>i</italic></sub>), the number of people actually with that strain of influenza (<inline-formula id="pcbi.1005838.e009"><alternatives><graphic xlink:href="pcbi.1005838.e009.jpg" id="pcbi.1005838.e009g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M9"><mml:msubsup><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mo>+</mml:mo></mml:msubsup></mml:math></alternatives></inline-formula>) and the total number of people (<italic>m</italic><sub><italic>i</italic></sub>). The second part of the likelihood function defines how the values <inline-formula id="pcbi.1005838.e010"><alternatives><graphic xlink:href="pcbi.1005838.e010.jpg" id="pcbi.1005838.e010g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M10"><mml:msubsup><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mo>+</mml:mo></mml:msubsup></mml:math></alternatives></inline-formula> and <italic>m</italic><sub><italic>i</italic></sub> depend on the ascertainment probability (<italic>&#x003f5;</italic><sub><italic>i</italic></sub>), external inflow of influenza (<italic>&#x003c8;</italic>) and the epidemiological model parameters (<italic>&#x003b8;</italic><sub><italic>i</italic></sub> = {&#x0039b;, <italic>&#x003c3;</italic><sub><italic>i</italic></sub>, <italic>I</italic><sub>0</sub>}, with <italic>I</italic><sub>0</sub> the log transformed initial infected population: <inline-formula id="pcbi.1005838.e011"><alternatives><graphic xlink:href="pcbi.1005838.e011.jpg" id="pcbi.1005838.e011g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M11"><mml:mrow><mml:msub><mml:mi>I</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mo form="prefix">log</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mi>i</mml:mi><mml:mn>1</mml:mn></mml:msubsup><mml:mrow><mml:mo>(</mml:mo><mml:mn>0</mml:mn><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula>). Here, subscript <italic>i</italic> designates the age group <italic>i</italic> and the parameters (<italic>&#x003f5;</italic><sub><italic>i</italic></sub>; <italic>&#x003c8;</italic>; &#x0039b;; <italic>&#x003c3;</italic><sub><italic>i</italic></sub>; <italic>I</italic><sub>0</sub>) are inferred from the data. We have no direct data for the number of people with a particular strain of influenza (<inline-formula id="pcbi.1005838.e012"><alternatives><graphic xlink:href="pcbi.1005838.e012.jpg" id="pcbi.1005838.e012g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M12"><mml:msubsup><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mo>+</mml:mo></mml:msubsup></mml:math></alternatives></inline-formula>) so we integrate over all possibilities, resulting in a computationally intensive calculation. For full details of the likelihood and the method of optimisation see [<xref rid="pcbi.1005838.ref006" ref-type="bibr">6</xref>].</p><p>Finally, an advanced MCMC algorithm is used to generate samples from the posterior distribution of the parameter values using this likelihood function [[<xref rid="pcbi.1005838.ref010" ref-type="bibr">10</xref>]; Algorithm 6B].</p><p>The use of the hypergeometric distribution and the resulting computational complexity of the likelihood function above is due to the fact that the source of data on influenza incidence is dual, composed of the ILI data, which is an umbrella for several respiratory infections and virology testing which indicates which of these diseases is circulating. The actual incidence of one particular pathogen can thus only be inferred by combining these two sources. When direct data on disease prevalence are available the <monospace>fluEvidenceSynthesis</monospace> package can still be used, by replacing the above likelihood function with a simplified likelihood function. The vignettes of the package provide in-depth information on how to replace the likelihood function, with a user-specified function.</p></sec><sec id="sec009"><title>Forward modelling</title><p>The resulting posterior samples of the parameters can be used to model alternative interventions and explore the changes in the resulting outbreak size. This is generally done by adapting the previously fitted epidemiological model to account for the new intervention strategy. This model is then run using the posterior parameter samples and the final disease burden can be compared under the current scenario and/or under alternative scenarios. The disease burden can also be used to calculate the cost and benefits of the alternative scenarios.</p></sec><sec id="sec010"><title>Cost effectiveness</title><p>The package provides a number of functions to aid with calculating the cost effectiveness. Based on existing mortality rate and data on hospitalised cases, the incidence number is transformed into the number of consultations, hospitalisations and deaths using the function <monospace>public_health_outcome(&#x02026;)</monospace>. These numbers can then be converted into the costs and the benefits in reduced consultations, hospitalisations and mortality due to alternative intervention methods. It is also possible to calculate the number of vaccine doses needed using the <monospace>vaccine_doses(&#x02026;)</monospace> function. Some of the rates and associated costs are country-specific as they depend on the healthcare system and therefore not included in the package.</p></sec></sec></sec><sec sec-type="results" id="sec011"><title>Results</title><p>We present an example examining the potential outbreak size reduction by extending the seasonal vaccination programme to include increased coverage in children aged 5-14 years. In this example we explore scenarios where either 40% or 80% coverage is achieved in the 5-14 year olds.</p><p>Following the workflow laid out in <xref ref-type="fig" rid="pcbi.1005838.g001">Fig 1</xref> we can divide the needed process as follows:</p><list list-type="simple"><list-item><p>1. Collect data for each season and subtype</p></list-item></list><p>The data available depends on the study area and collection agency, so this step is variable. Examples of the needed layout using UK data are provided with the package and can be used to base your data format on.</p><list list-type="simple"><list-item><p>2. Run inference (for each season and subtype)</p></list-item></list><p>Performing the default parameter inference implemented in this package (see [<xref rid="pcbi.1005838.ref006" ref-type="bibr">6</xref>]) using user-specified data is straightforward by running the analysis using the <monospace>inference(&#x02026;)</monospace> function, that needs to be run for each season and strain (as illustrated in the R (pseudo)code example below). Note that for performance reasons it is advised to adapt this pseudocode to run in parallel for each season and strain.</p><boxed-text id="pcbi.1005838.box001" position="float" orientation="portrait"><p><monospace>inference.results &#x0003c;- <inline-formula id="pcbi.1005838.e013"><alternatives><graphic xlink:href="pcbi.1005838.e013.jpg" id="pcbi.1005838.e013g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M13"><mml:mrow><mml:mtext mathcolor="#214a87">list</mml:mtext></mml:mrow></mml:math></alternatives></inline-formula>()</monospace></p><p><monospace>for (season in seasons) {</monospace></p><p><monospace>&#x02003;for (subtype in subtypes) {</monospace></p><p><monospace>&#x02003;&#x02003;inference.results[[season]][[subtype]] &#x0003c;-</monospace></p><p><monospace>&#x02003;&#x02003;&#x02003;<inline-formula id="pcbi.1005838.e014"><alternatives><graphic xlink:href="pcbi.1005838.e014.jpg" id="pcbi.1005838.e014g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M14"><mml:mrow><mml:mtext mathcolor="#214a87">inference</mml:mtext></mml:mrow></mml:math></alternatives></inline-formula>(demography[[season]], ili[[season]][[subtype]], &#x02026;)</monospace></p><p><monospace>&#x02003;}</monospace></p><p><monospace>}</monospace></p></boxed-text><p>The <monospace>inference(&#x02026;)</monospace> function is a high level function that implements the whole inference part of the workflow. This function takes all the data (as described earlier in this manuscript) and returns posterior samples of the parameters. The documentation of the package also shows how to adapt parts of the inference function for use with a different underlying epidemiological model, or different likelihood function. <xref ref-type="fig" rid="pcbi.1005838.g002">Fig 2</xref> highlights the difference between our prior distribution of <italic>R</italic><sub>0</sub> and the posterior distribution of <italic>R</italic><sub>0</sub> following parameter inference. In the 2007/08 season the posterior is very similar to the prior. This is probably because in that season the incidence of H3N2 was very low compared to the other two seasons shown here.</p><fig id="pcbi.1005838.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1005838.g002</object-id><label>Fig 2</label><caption><title>Posterior and prior probability of R0 for different seasons and serotype H3N2.</title></caption><graphic xlink:href="pcbi.1005838.g002"/></fig><list list-type="simple"><list-item><p>3. Forward modelling</p></list-item></list><list list-type="bullet"><list-item><p>Define alternative scenario</p></list-item></list><p>Any vaccination scenario depends on the efficacy of the vaccine, the total vaccine uptake, and the relative rate of uptake over time (e.g. during the first month the uptake rate in the UK is higher than in later months). To model our scenario we scaled the total uptake rate to 40% and 80%, while keeping the other factors constant. This was achieved by calculating the total uptake rate for the relevant age group (i.e. <italic>V</italic> = &#x0222b; <italic>v</italic>(<italic>t</italic>)d<italic>t</italic>) and scaling up the original uptake rate to result in a total coverage of <italic>V</italic><sub><italic>s</italic></sub> = 0.4 or <italic>V</italic><sub><italic>s</italic></sub> = 0.8 (i.e. <inline-formula id="pcbi.1005838.e015"><alternatives><graphic xlink:href="pcbi.1005838.e015.jpg" id="pcbi.1005838.e015g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M15"><mml:mrow><mml:mover accent="true"><mml:mi>v</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:msub><mml:mi>V</mml:mi><mml:mi>s</mml:mi></mml:msub><mml:mi>v</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mi>V</mml:mi></mml:mrow></mml:math></alternatives></inline-formula>).</p><list list-type="bullet"><list-item><p>Run vaccination scenario for all results with old vs. new scenario</p></list-item></list><p>The inference step results in a number of posterior samples for the parameters and contact data. We can now use these samples and model the outcome of our alternative vaccination scenario. Then we calculate the difference in influenza burden between the original and our alternative vaccination scenarios. This is done by taking samples from each season and strain combination and calculating the disease burden over all the seasons/strains of the new scenario relative to the original scenario (using the <monospace>vaccination_scenario(&#x02026;)</monospace> function). The results are summarized in <xref ref-type="fig" rid="pcbi.1005838.g003">Fig 3</xref>, showing a reduction of influenza cases in both the low and high risk groups under the new scenario. The magnitude of the reduction is dependent on the level of vaccine coverage. The higher coverage (80%) results in a reduction of around 5.9 million, while lower coverage (40%) results in a reduction of influenza cases of approximately 3.5 million (<xref ref-type="fig" rid="pcbi.1005838.g003">Fig 3</xref>).</p><fig id="pcbi.1005838.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1005838.g003</object-id><label>Fig 3</label><caption><title>Reduction in influenza incidence under increased vaccination of the age group between 5 and 15.</title><p>The orange colour signifies the reduction in patients classified as high risk. The blue colour is the reduction in the low risk population. The first results correspond to a scenario where 40 percent coverage is achieved, the second to a coverage of 80.</p></caption><graphic xlink:href="pcbi.1005838.g003"/></fig><list list-type="simple"><list-item><p>4. Cost effectiveness</p></list-item></list><p>Performing the cost effectiveness analysis requires calculating the costs and benefits of the proposed intervention. The main cost in increasing vaccination stems from administering additional vaccine doses, which can be calculated with the <monospace>vaccine_doses(&#x02026;)</monospace> function. Resulting benefits will mostly come from associated decreases in the number of consultations, reduced hospital admissions and finally reduced mortality. Generally, these values are calculated as the proportion of influenza cases that result in consultations, hospital admissions etc. The pseudocode below shows how to calculate the cost associated with a new vaccine calendar, assuming that 7% of infected people visit the GP and 0.2% and 2% of infected individuals are hospitalised for the low risk and high risk groups respectively.</p><boxed-text id="pcbi.1005838.box002" position="float" orientation="portrait"><p><monospace>posterior_cost &#x0003c;- <inline-formula id="pcbi.1005838.e016"><alternatives><graphic xlink:href="pcbi.1005838.e016.jpg" id="pcbi.1005838.e016g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M16"><mml:mrow><mml:mtext mathcolor="#214a87">rep</mml:mtext></mml:mrow></mml:math></alternatives></inline-formula>(<inline-formula id="pcbi.1005838.e017"><alternatives><graphic xlink:href="pcbi.1005838.e017.jpg" id="pcbi.1005838.e017g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M17"><mml:mrow><mml:mn mathcolor="#0000cf">0</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>, nbatch)</monospace></p><p><monospace>for (season in seasons) {</monospace></p><p><monospace>&#x02003;<inline-formula id="pcbi.1005838.e018"><alternatives><graphic xlink:href="pcbi.1005838.e018.jpg" id="pcbi.1005838.e018g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M18"><mml:mrow><mml:mi mathcolor="#8f5903">#</mml:mi><mml:mspace width="1pt"/><mml:mtext mathcolor="#8f5903" mathvariant="italic">Vaccine</mml:mtext><mml:mspace width="1pt"/><mml:mtext mathcolor="#8f5903" mathvariant="italic">price</mml:mtext><mml:mspace width="1pt"/><mml:mtext mathcolor="#8f5903" mathvariant="italic">covers</mml:mtext><mml:mspace width="1pt"/><mml:mtext mathcolor="#8f5903" mathvariant="italic">all</mml:mtext><mml:mspace width="1pt"/><mml:mtext mathcolor="#8f5903" mathvariant="italic">subtypes</mml:mtext></mml:mrow></mml:math></alternatives></inline-formula></monospace></p><p><monospace>&#x02003;posterior_cost &#x0003c;- posterior_cost +</monospace></p><p><monospace>&#x02003;&#x02003;<inline-formula id="pcbi.1005838.e019"><alternatives><graphic xlink:href="pcbi.1005838.e019.jpg" id="pcbi.1005838.e019g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M19"><mml:mrow><mml:mtext mathcolor="#214a87">rep</mml:mtext></mml:mrow></mml:math></alternatives></inline-formula>(vaccine_price*</monospace></p><p><monospace>&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;(<inline-formula id="pcbi.1005838.e020"><alternatives><graphic xlink:href="pcbi.1005838.e020.jpg" id="pcbi.1005838.e020g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M20"><mml:mrow><mml:mtext mathcolor="#214a87">vaccine_doses</mml:mtext></mml:mrow></mml:math></alternatives></inline-formula>(proposed_calender) - <inline-formula id="pcbi.1005838.e021"><alternatives><graphic xlink:href="pcbi.1005838.e021.jpg" id="pcbi.1005838.e021g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M21"><mml:mrow><mml:mtext mathcolor="#214a87">vaccine_doses</mml:mtext></mml:mrow></mml:math></alternatives></inline-formula>(calendar)), nbatch)</monospace></p><p><monospace>&#x02003;for (subtype in subtypes) {</monospace></p><p><monospace>&#x02003;&#x02003;<inline-formula id="pcbi.1005838.e022"><alternatives><graphic xlink:href="pcbi.1005838.e022.jpg" id="pcbi.1005838.e022g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M22"><mml:mrow><mml:mi mathcolor="#8f5903">#</mml:mi><mml:mspace width="1pt"/><mml:mtext mathcolor="#8f5903" mathvariant="italic">Calculate</mml:mtext><mml:mspace width="1pt"/><mml:mtext mathcolor="#8f5903" mathvariant="italic">incidence</mml:mtext><mml:mspace width="1pt"/><mml:mtext mathcolor="#8f5903" mathvariant="italic">of</mml:mtext><mml:mspace width="1pt"/><mml:mtext mathcolor="#8f5903" mathvariant="italic">different</mml:mtext><mml:mspace width="1pt"/><mml:mtext mathcolor="#8f5903" mathvariant="italic">outcomes</mml:mtext></mml:mrow></mml:math></alternatives></inline-formula></monospace></p><p><monospace>&#x02003;&#x02003;outcomes &#x0003c;- <inline-formula id="pcbi.1005838.e023"><alternatives><graphic xlink:href="pcbi.1005838.e023.jpg" id="pcbi.1005838.e023g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M23"><mml:mrow><mml:mtext mathcolor="#214a87">rowSums</mml:mtext></mml:mrow></mml:math></alternatives></inline-formula>(<inline-formula id="pcbi.1005838.e024"><alternatives><graphic xlink:href="pcbi.1005838.e024.jpg" id="pcbi.1005838.e024g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M24"><mml:mrow><mml:mtext mathcolor="#214a87">public_health_outcome</mml:mtext></mml:mrow></mml:math></alternatives></inline-formula>(</monospace></p><p><monospace>&#x02003;&#x02003;&#x02003;<inline-formula id="pcbi.1005838.e025"><alternatives><graphic xlink:href="pcbi.1005838.e025.jpg" id="pcbi.1005838.e025g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M25"><mml:mrow><mml:mtext mathcolor="#214a87">list</mml:mtext></mml:mrow></mml:math></alternatives></inline-formula>(<inline-formula id="pcbi.1005838.e026"><alternatives><graphic xlink:href="pcbi.1005838.e026.jpg" id="pcbi.1005838.e026g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M26"><mml:mrow><mml:mo mathcolor="#4f9905">"</mml:mo><mml:mtext mathcolor="#4f9905">gp</mml:mtext><mml:mo mathcolor="#4f9905">"</mml:mo></mml:mrow></mml:math></alternatives></inline-formula> = <inline-formula id="pcbi.1005838.e027"><alternatives><graphic xlink:href="pcbi.1005838.e027.jpg" id="pcbi.1005838.e027g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M27"><mml:mrow><mml:mn mathcolor="#0000cf">0.07</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>, <inline-formula id="pcbi.1005838.e028"><alternatives><graphic xlink:href="pcbi.1005838.e028.jpg" id="pcbi.1005838.e028g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M28"><mml:mrow><mml:mo mathcolor="#4f9905">"</mml:mo><mml:mtext mathcolor="#4f9905">hospital</mml:mtext><mml:mo mathcolor="#4f9905">"</mml:mo></mml:mrow></mml:math></alternatives></inline-formula> = <inline-formula id="pcbi.1005838.e029"><alternatives><graphic xlink:href="pcbi.1005838.e029.jpg" id="pcbi.1005838.e029g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M29"><mml:mrow><mml:mtext mathcolor="#214a87">c</mml:mtext></mml:mrow></mml:math></alternatives></inline-formula>(<inline-formula id="pcbi.1005838.e030"><alternatives><graphic xlink:href="pcbi.1005838.e030.jpg" id="pcbi.1005838.e030g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M30"><mml:mrow><mml:mn mathcolor="#0000cf">0.002</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>, <inline-formula id="pcbi.1005838.e031"><alternatives><graphic xlink:href="pcbi.1005838.e031.jpg" id="pcbi.1005838.e031g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M31"><mml:mrow><mml:mn mathcolor="#0000cf">0.02</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>)),</monospace></p><p><monospace>&#x02003;&#x02003;&#x02003;&#x02003;<inline-formula id="pcbi.1005838.e032"><alternatives><graphic xlink:href="pcbi.1005838.e032.jpg" id="pcbi.1005838.e032g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M32"><mml:mrow><mml:mtext mathcolor="#214a87">vaccination_scenario</mml:mtext></mml:mrow></mml:math></alternatives></inline-formula>(<inline-formula id="pcbi.1005838.e033"><alternatives><graphic xlink:href="pcbi.1005838.e033.jpg" id="pcbi.1005838.e033g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M33"><mml:mrow><mml:mtext mathcolor="#214a87">vaccine_calendar</mml:mtext><mml:mspace width="1pt"/><mml:mo mathcolor="#214a87">=</mml:mo></mml:mrow></mml:math></alternatives></inline-formula> calendar, &#x02026;), &#x02026;))</monospace></p><p><monospace>&#x02003;&#x02003;<inline-formula id="pcbi.1005838.e034"><alternatives><graphic xlink:href="pcbi.1005838.e034.jpg" id="pcbi.1005838.e034g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M34"><mml:mrow><mml:mi mathcolor="#8f5903">#</mml:mi><mml:mspace width="1pt"/><mml:mtext mathcolor="#8f5903" mathvariant="italic">Calculate</mml:mtext><mml:mspace width="1pt"/><mml:mtext mathcolor="#8f5903" mathvariant="italic">incidence</mml:mtext><mml:mspace width="1pt"/><mml:mtext mathcolor="#8f5903" mathvariant="italic">of</mml:mtext><mml:mspace width="1pt"/><mml:mtext mathcolor="#8f5903" mathvariant="italic">different</mml:mtext><mml:mspace width="1pt"/><mml:mtext mathcolor="#8f5903" mathvariant="italic">outcomes</mml:mtext><mml:mspace width="1pt"/><mml:mtext mathcolor="#8f5903" mathvariant="italic">under</mml:mtext><mml:mspace width="1pt"/><mml:mtext mathcolor="#8f5903" mathvariant="italic">proposed</mml:mtext><mml:mspace width="1pt"/><mml:mtext mathcolor="#8f5903" mathvariant="italic">policy</mml:mtext></mml:mrow></mml:math></alternatives></inline-formula></monospace></p><p><monospace>&#x02003;&#x02003;new_outc &#x0003c;- <inline-formula id="pcbi.1005838.e035"><alternatives><graphic xlink:href="pcbi.1005838.e035.jpg" id="pcbi.1005838.e035g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M35"><mml:mrow><mml:mtext mathcolor="#214a87">rowSums</mml:mtext></mml:mrow></mml:math></alternatives></inline-formula>(<inline-formula id="pcbi.1005838.e036"><alternatives><graphic xlink:href="pcbi.1005838.e036.jpg" id="pcbi.1005838.e036g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M36"><mml:mrow><mml:mtext mathcolor="#214a87">public_health_outcome</mml:mtext></mml:mrow></mml:math></alternatives></inline-formula>(</monospace></p><p><monospace>&#x02003;&#x02003;&#x02003;<inline-formula id="pcbi.1005838.e037"><alternatives><graphic xlink:href="pcbi.1005838.e037.jpg" id="pcbi.1005838.e037g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M37"><mml:mrow><mml:mtext mathcolor="#214a87">list</mml:mtext></mml:mrow></mml:math></alternatives></inline-formula>(<inline-formula id="pcbi.1005838.e038"><alternatives><graphic xlink:href="pcbi.1005838.e038.jpg" id="pcbi.1005838.e038g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M38"><mml:mrow><mml:mo mathcolor="#4f9905">"</mml:mo><mml:mtext mathcolor="#4f9905">gp</mml:mtext><mml:mo mathcolor="#4f9905">"</mml:mo></mml:mrow></mml:math></alternatives></inline-formula> = <inline-formula id="pcbi.1005838.e039"><alternatives><graphic xlink:href="pcbi.1005838.e039.jpg" id="pcbi.1005838.e039g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M39"><mml:mrow><mml:mn mathcolor="#0000cf">0.07</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>, <inline-formula id="pcbi.1005838.e040"><alternatives><graphic xlink:href="pcbi.1005838.e040.jpg" id="pcbi.1005838.e040g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M40"><mml:mrow><mml:mo mathcolor="#4f9905">"</mml:mo><mml:mtext mathcolor="#4f9905">hospital</mml:mtext><mml:mo mathcolor="#4f9905">"</mml:mo></mml:mrow></mml:math></alternatives></inline-formula> = <inline-formula id="pcbi.1005838.e041"><alternatives><graphic xlink:href="pcbi.1005838.e041.jpg" id="pcbi.1005838.e041g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M41"><mml:mrow><mml:mtext mathcolor="#214a87">c</mml:mtext></mml:mrow></mml:math></alternatives></inline-formula>(<inline-formula id="pcbi.1005838.e042"><alternatives><graphic xlink:href="pcbi.1005838.e042.jpg" id="pcbi.1005838.e042g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M42"><mml:mrow><mml:mn mathcolor="#0000cf">0.002</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>, <inline-formula id="pcbi.1005838.e043"><alternatives><graphic xlink:href="pcbi.1005838.e043.jpg" id="pcbi.1005838.e043g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M43"><mml:mrow><mml:mn mathcolor="#0000cf">0.02</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>)),</monospace></p><p><monospace>&#x02003;&#x02003;&#x02003;&#x02003;<inline-formula id="pcbi.1005838.e044"><alternatives><graphic xlink:href="pcbi.1005838.e044.jpg" id="pcbi.1005838.e044g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M44"><mml:mrow><mml:mtext mathcolor="#214a87">vaccination_scenario</mml:mtext></mml:mrow></mml:math></alternatives></inline-formula>(<inline-formula id="pcbi.1005838.e045"><alternatives><graphic xlink:href="pcbi.1005838.e045.jpg" id="pcbi.1005838.e045g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M45"><mml:mrow><mml:mtext mathcolor="#214a87">vaccine_calendar</mml:mtext><mml:mspace width="1pt"/><mml:mo mathcolor="#214a87">=</mml:mo></mml:mrow></mml:math></alternatives></inline-formula> proposed_calendar, &#x02026;), &#x02026;))</monospace></p><p><monospace>&#x02003;&#x02003;<inline-formula id="pcbi.1005838.e046"><alternatives><graphic xlink:href="pcbi.1005838.e046.jpg" id="pcbi.1005838.e046g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M46"><mml:mrow><mml:mi mathcolor="#8f5903">#</mml:mi><mml:mspace width="1pt"/><mml:mtext mathcolor="#8f5903" mathvariant="italic">Difference</mml:mtext><mml:mspace width="1pt"/><mml:mtext mathcolor="#8f5903" mathvariant="italic">of</mml:mtext><mml:mspace width="1pt"/><mml:mtext mathcolor="#8f5903" mathvariant="italic">cost</mml:mtext><mml:mspace width="1pt"/><mml:mtext mathcolor="#8f5903" mathvariant="italic">under</mml:mtext><mml:mspace width="1pt"/><mml:mtext mathcolor="#8f5903" mathvariant="italic">new</mml:mtext><mml:mspace width="1pt"/><mml:mtext mathcolor="#8f5903" mathvariant="italic">intervention</mml:mtext><mml:mspace width="1pt"/><mml:mtext mathcolor="#8f5903" mathvariant="italic">versus</mml:mtext><mml:mspace width="1pt"/><mml:mtext mathcolor="#8f5903" mathvariant="italic">existing</mml:mtext><mml:mspace width="1pt"/><mml:mtext mathcolor="#8f5903" mathvariant="italic">policy</mml:mtext></mml:mrow></mml:math></alternatives></inline-formula></monospace></p><p><monospace>&#x02003;&#x02003;posterior_cost &#x0003c;- posterior_cost +</monospace></p><p><monospace>&#x02003;&#x02003;&#x02003;gp_cost*(new_outc$gp - outcomes$gp) +</monospace></p><p><monospace>&#x02003;&#x02003;&#x02003;hospital_cost*(new_outc$hospital - outcomes$hospital)</monospace></p><p><monospace>&#x02003;}</monospace></p><p><monospace>}</monospace></p><p><monospace>posterior_cost &#x0003c;- posterior_cost/<inline-formula id="pcbi.1005838.e047"><alternatives><graphic xlink:href="pcbi.1005838.e047.jpg" id="pcbi.1005838.e047g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M47"><mml:mrow><mml:mtext mathcolor="#214a87">length</mml:mtext></mml:mrow></mml:math></alternatives></inline-formula>(seasons) <inline-formula id="pcbi.1005838.e048"><alternatives><graphic xlink:href="pcbi.1005838.e048.jpg" id="pcbi.1005838.e048g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M48"><mml:mrow><mml:mi mathcolor="#8f5903">#</mml:mi><mml:mspace width="1pt"/><mml:mtext mathcolor="#8f5903" mathvariant="italic">Per</mml:mtext><mml:mspace width="1pt"/><mml:mtext mathcolor="#8f5903" mathvariant="italic">season</mml:mtext></mml:mrow></mml:math></alternatives></inline-formula></monospace></p></boxed-text><p>Another important aspect of cost effectiveness calculations is the reduction of mortality due to incidence reduction. <xref ref-type="fig" rid="pcbi.1005838.g004">Fig 4</xref> shows the cost of different vaccination scenarios as a function of reduction in mortality. More sophisticated cost effectiveness analysis could also take into account the risk and cost of hospitalisation as well as indirect effects due to increased vaccine-induced immunity in the population.</p><fig id="pcbi.1005838.g004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1005838.g004</object-id><label>Fig 4</label><caption><title>Cost effectiveness analysis showing the vaccine cost by reduction in mortality under two vaccination scenarios, taking into account uncertainty in vaccine cost, influenza incidence and death risk.</title><p>The colours represent the uncertainty around the different scenarios. The lines represent two potential thresholds: (1) for a cost of up to 1000 for each life saved both programmes are not cost effective, (2) for a cost up to 10,000 per life saved both programmes are likely to be cost effective. The parameter values used in this figure (cost of vaccine: 17 &#x000b1; 2.5 and mortality risk: 0.0025 &#x000b1; 0.0005) were chosen for illustrative purposes only and should not be taken as realistic values.</p></caption><graphic xlink:href="pcbi.1005838.g004"/></fig></sec><sec id="sec012"><title>Availability and future directions</title><p>The R package we presented here was developed to make advanced analysis of disease dynamics more approachable for data analysts and scientists interested in public health related questions. The package implemented the whole process of preparing the data, running the model, inferring posterior parameter distributions and performing cost effectiveness analysis. The approach implemented is based on the method by [<xref rid="pcbi.1005838.ref006" ref-type="bibr">6</xref>] and [<xref rid="pcbi.1005838.ref007" ref-type="bibr">7</xref>]. The package is modular in design, such that the method can be adapted by, for example, changing the underlying epidemiological model and/or likelihood function. While advanced methods such as implemented in this package are inherently complex and traditionally applied by specialised researchers, the package is designed to make the analysis accessible to a wider group of researchers. The package is freely available under the GPL-3.0 license on github at <ext-link ext-link-type="uri" xlink:href="https://github.com/MJomaba/flu-evidence-synthesis">https://github.com/MJomaba/flu-evidence-synthesis</ext-link>.</p><sec id="sec013"><title>Contact matrix</title><p>Currently no explicit model of contact rates is included and inference of the contact matrix is performed by bootstrapping the available contact data [<xref rid="pcbi.1005838.ref006" ref-type="bibr">6</xref>]. One model we are working on is to use demographic data to inform contact inference, similar to the approach explored by [<xref rid="pcbi.1005838.ref011" ref-type="bibr">11</xref>]. Another simplification in the current approach is the assumption that the contact matrix is constant throughout the season. Indeed, contact matrices are dependent on behaviour and this can change during the year [<xref rid="pcbi.1005838.ref012" ref-type="bibr">12</xref>], either due to external drivers (e.g. school vacation) or in response to influenza (e.g. staying at home when sick [<xref rid="pcbi.1005838.ref013" ref-type="bibr">13</xref>]). These changes in behaviour could then be incorporated into the contact model. Due to the modularity of the package it is possible to plug-in such a contact model and explore its effect on intervention strategies.</p></sec><sec id="sec014"><title>Multi-year</title><p>The package simulates each strain and season independently. An interesting possible addition would be to implement multi-year models, i.e. models where the current state is influenced by the previous years results. One possible approach would be to use the posterior of the previous season as a prior for the next season, but that would not capture dynamic effects of alternative vaccination strategies. Capturing long-term dynamic effects requires an explicit multi-year epidemiological model, which introduces challenges of modelling antigenic evolution of antigenic strains as well as waning of immunity [<xref rid="pcbi.1005838.ref014" ref-type="bibr">14</xref>&#x02013;<xref rid="pcbi.1005838.ref016" ref-type="bibr">16</xref>]. Such a model would need to be calibrated jointly to multiple sources of data (e.g. DNA sequences, syndromic surveillance, serology, demography) [<xref rid="pcbi.1005838.ref017" ref-type="bibr">17</xref>].</p></sec><sec id="sec015"><title>Beyond influenza</title><p>The package has been developed with a focus on influenza data, but could potentially be adapted to predict the impact and cost effectiveness for a range of interventions for other infectious diseases. The parts that are disease specific are the likelihood function and the transmission model. The transmission model is an SEIR model which can be used to capture a wide variety of diseases. If this model is not suitable for your analysis then it is of course possible to replace it with another model while still using the other parts of the package.</p><p>The likelihood function is suitable for any disease where most of the data on disease occurrence is a proxy for the actual occurrence, augmented with a smaller source of direct data (virological). If more direct data are available then it might be appropriate to replace the current likelihood function with a (simplified) likelihood that is only based on the direct data.</p></sec><sec id="sec016"><title>Conclusion</title><p>The <monospace>fluEvidenceSynthesis</monospace> package implements the needed pipeline to go from raw epidemiological data to a cost effectiveness analysis based on Bayesian inference methods. The workflow implemented is based on the analysis used to predict the cost effectiveness of paediatric vaccination in the UK [<xref rid="pcbi.1005838.ref006" ref-type="bibr">6</xref>,<xref rid="pcbi.1005838.ref007" ref-type="bibr">7</xref>]. The package itself has been successfully used in further analyses, most notably [<xref rid="pcbi.1005838.ref018" ref-type="bibr">18</xref>] and [<xref rid="pcbi.1005838.ref019" ref-type="bibr">19</xref>]. Feedback from those analyses has been used to improve the package. It is implemented as a series of loosely connected steps and allows the researcher to replace any of these phases with their own method.</p></sec></sec></body><back><ack><p>We would like to thank Thibaut Jombart and Rich Fitzjohn from the R Epidemics Consortium (RECON; <ext-link ext-link-type="uri" xlink:href="http://www.repidemicsconsortium.org">http://www.repidemicsconsortium.org</ext-link>) for guidelines and advice on development of R-packages for analysing epidemics. The research was performed in partnership with Public Health England (PHE). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, the Department of Health or Public Health England.</p></ack><ref-list><title>References</title><ref id="pcbi.1005838.ref001"><label>1</label><mixed-citation publication-type="other">Aragon TJ. Epitools: Epidemiology Tools. R package version 0.5-7. 2012; Available: <ext-link ext-link-type="uri" xlink:href="http://CRAN.R-project.org/package=epitools">http://CRAN.R-project.org/package=epitools</ext-link></mixed-citation></ref><ref id="pcbi.1005838.ref002"><label>2</label><mixed-citation publication-type="other">Carstensen B, Plummer M, Laara E, Hills M. Epi: A Package for Statistical Analysis in Epidemiology. R package version 2.0]. 2016; Available: <ext-link ext-link-type="uri" xlink:href="http://CRAN.R-project.org/package=Epi">http://CRAN.R-project.org/package=Epi</ext-link></mixed-citation></ref><ref id="pcbi.1005838.ref003"><label>3</label><mixed-citation publication-type="other">Therneau TM. Survival: Survival Analysis. R package version 2.38-3. 2015; Available: <ext-link ext-link-type="uri" xlink:href="http://CRAN.R-project.org/package=survival">http://CRAN.R-project.org/package=survival</ext-link></mixed-citation></ref><ref id="pcbi.1005838.ref004"><label>4</label><mixed-citation publication-type="journal">
<name><surname>Merl</surname><given-names>D</given-names></name>, <name><surname>Johnson</surname><given-names>L</given-names></name>, <name><surname>Gramacy</surname><given-names>R</given-names></name>, <name><surname>Mangel</surname><given-names>M</given-names></name>. <article-title>Amei: An R Package for the Adaptive Management of Epidemiological Interventions</article-title>. <source>Journal of Statistical Software</source>. <year>2010</year>;<volume>36</volume>: <fpage>1</fpage>&#x02013;<lpage>32</lpage>.</mixed-citation></ref><ref id="pcbi.1005838.ref005"><label>5</label><mixed-citation publication-type="journal">
<name><surname>Baguelin</surname><given-names>M</given-names></name>, <name><surname>Hoek</surname><given-names>AJV</given-names></name>, <name><surname>Jit</surname><given-names>M</given-names></name>, <name><surname>Flasche</surname><given-names>S</given-names></name>, <name><surname>White</surname><given-names>PJ</given-names></name>, <name><surname>Edmunds</surname><given-names>WJ</given-names></name>. <article-title>Vaccination against pandemic influenza A/H1N1v in England: A real-time economic evaluation</article-title>. <source>Vaccine</source>. <year>2010</year>;<volume>28</volume>: <fpage>2370</fpage>&#x02013;<lpage>2384</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.vaccine.2010.01.002">10.1016/j.vaccine.2010.01.002</ext-link></comment>
<?supplied-pmid 20096762?><pub-id pub-id-type="pmid">20096762</pub-id></mixed-citation></ref><ref id="pcbi.1005838.ref006"><label>6</label><mixed-citation publication-type="journal">
<name><surname>Baguelin</surname><given-names>M</given-names></name>, <name><surname>Flasche</surname><given-names>S</given-names></name>, <name><surname>Camacho</surname><given-names>A</given-names></name>, <name><surname>Demiris</surname><given-names>N</given-names></name>, <name><surname>Miller</surname><given-names>E</given-names></name>, <name><surname>Edmunds</surname><given-names>WJ</given-names></name>. <article-title>Assessing Optimal Target Populations for Influenza Vaccination Programmes: An Evidence Synthesis and Modelling Study</article-title>. <source>PLoS Med</source>. <year>2013</year>;<volume>10</volume>: <fpage>e1001527</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pmed.1001527">10.1371/journal.pmed.1001527</ext-link></comment>
<?supplied-pmid 24115913?><pub-id pub-id-type="pmid">24115913</pub-id></mixed-citation></ref><ref id="pcbi.1005838.ref007"><label>7</label><mixed-citation publication-type="journal">
<name><surname>Baguelin</surname><given-names>M</given-names></name>, <name><surname>Camacho</surname><given-names>A</given-names></name>, <name><surname>Flasche</surname><given-names>S</given-names></name>, <name><surname>Edmunds</surname><given-names>WJ</given-names></name>. <article-title>Extending the elderly- and risk-group programme of vaccination against seasonal influenza in England and Wales: A cost-effectiveness study</article-title>. <source>BMC Medicine</source>. <year>2015</year>;<volume>13</volume>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/s12916-015-0452-y">10.1186/s12916-015-0452-y</ext-link></comment>
<?supplied-pmid 26459265?><pub-id pub-id-type="pmid">26459265</pub-id></mixed-citation></ref><ref id="pcbi.1005838.ref008"><label>8</label><mixed-citation publication-type="journal">
<name><surname>Mossong</surname><given-names>J</given-names></name>, <name><surname>Hens</surname><given-names>N</given-names></name>, <name><surname>Jit</surname><given-names>M</given-names></name>, <name><surname>Beutels</surname><given-names>P</given-names></name>, <name><surname>Auranen</surname><given-names>K</given-names></name>, <name><surname>Mikolajczyk</surname><given-names>R</given-names></name>, <etal>et al</etal>
<article-title>Social contacts and mixing patterns relevant to the spread of infectious diseases</article-title>. <source>PLoS Med</source>. <year>2008</year>;<volume>5</volume>: <fpage>e74</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pmed.0050074">10.1371/journal.pmed.0050074</ext-link></comment>
<?supplied-pmid 18366252?><pub-id pub-id-type="pmid">18366252</pub-id></mixed-citation></ref><ref id="pcbi.1005838.ref009"><label>9</label><mixed-citation publication-type="journal">
<name><surname>Fiore</surname><given-names>AE</given-names></name>, <name><surname>Shay</surname><given-names>DK</given-names></name>, <name><surname>Broder</surname><given-names>K</given-names></name>, <name><surname>Iskander</surname><given-names>JK</given-names></name>, <name><surname>Uyeki</surname><given-names>TM</given-names></name>, <name><surname>Mootrey</surname><given-names>G</given-names></name>, <etal>et al</etal>
<article-title>Prevention and control of seasonal influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009</article-title>. <source>MMWR Recomm Rep</source>. <year>2009</year>;<volume>58</volume>: <fpage>1</fpage>&#x02013;<lpage>52</lpage>. <?supplied-pmid 19644442?><pub-id pub-id-type="pmid">19644442</pub-id></mixed-citation></ref><ref id="pcbi.1005838.ref010"><label>10</label><mixed-citation publication-type="journal">
<name><surname>Sherlock</surname><given-names>C</given-names></name>, <name><surname>Fearnhead</surname><given-names>P</given-names></name>, <name><surname>Roberts</surname><given-names>GO</given-names></name>. <article-title>The Random Walk Metropolis: Linking Theory and Practice Through a Case Study</article-title>. <source>Statistical Science</source>. <year>2010</year>;<volume>25</volume>: <fpage>172</fpage>&#x02013;<lpage>190</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1214/10-STS327">10.1214/10-STS327</ext-link></comment></mixed-citation></ref><ref id="pcbi.1005838.ref011"><label>11</label><mixed-citation publication-type="journal">
<name><surname>Fumanelli</surname><given-names>L</given-names></name>, <name><surname>Ajelli</surname><given-names>M</given-names></name>, <name><surname>Manfredi</surname><given-names>P</given-names></name>, <name><surname>Vespignani</surname><given-names>A</given-names></name>, <name><surname>Merler</surname><given-names>S</given-names></name>. <article-title>Inferring the Structure of Social Contacts from Demographic Data in the Analysis of Infectious Diseases Spread</article-title>. <source>PLoS Comput Biol</source>. <year>2012</year>;<volume>8</volume>: <fpage>e1002673</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pcbi.1002673">10.1371/journal.pcbi.1002673</ext-link></comment>
<?supplied-pmid 23028275?><pub-id pub-id-type="pmid">23028275</pub-id></mixed-citation></ref><ref id="pcbi.1005838.ref012"><label>12</label><mixed-citation publication-type="journal">
<name><surname>Dureau</surname><given-names>J</given-names></name>, <name><surname>Kalogeropoulos</surname><given-names>K</given-names></name>, <name><surname>Baguelin</surname><given-names>M</given-names></name>. <article-title>Capturing the time-varying drivers of an epidemic using stochastic dynamical systems</article-title>. <source>Biostat</source>. <year>2013</year>;<volume>14</volume>: <fpage>541</fpage>&#x02013;<lpage>555</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/biostatistics/kxs052">10.1093/biostatistics/kxs052</ext-link></comment></mixed-citation></ref><ref id="pcbi.1005838.ref013"><label>13</label><mixed-citation publication-type="journal">
<name><surname>Van Kerckhove</surname><given-names>K</given-names></name>, <name><surname>Hens</surname><given-names>N</given-names></name>, <name><surname>Edmunds</surname><given-names>WJ</given-names></name>, <name><surname>Eames</surname><given-names>KTD</given-names></name>. <article-title>The Impact of Illness on Social Networks: Implications for Transmission and Control of Influenza</article-title>. <source>Am J Epidemiol</source>. <year>2013</year>;<volume>178</volume>: <fpage>1655</fpage>&#x02013;<lpage>1662</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/aje/kwt196">10.1093/aje/kwt196</ext-link></comment>
<?supplied-pmid 24100954?><pub-id pub-id-type="pmid">24100954</pub-id></mixed-citation></ref><ref id="pcbi.1005838.ref014"><label>14</label><mixed-citation publication-type="journal">
<name><surname>Smith</surname><given-names>DJ</given-names></name>, <name><surname>Lapedes</surname><given-names>AS</given-names></name>, <name><surname>Jong</surname><given-names>JC de</given-names></name>, <name><surname>Bestebroer</surname><given-names>TM</given-names></name>, <name><surname>Rimmelzwaan</surname><given-names>GF</given-names></name>, <name><surname>Osterhaus</surname><given-names>ADME</given-names></name>, <etal>et al</etal>
<article-title>Mapping the Antigenic and Genetic Evolution of Influenza Virus</article-title>. <source>Science</source>. <year>2004</year>;<volume>305</volume>: <fpage>371</fpage>&#x02013;<lpage>376</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1126/science.1097211">10.1126/science.1097211</ext-link></comment>
<?supplied-pmid 15218094?><pub-id pub-id-type="pmid">15218094</pub-id></mixed-citation></ref><ref id="pcbi.1005838.ref015"><label>15</label><mixed-citation publication-type="journal">
<name><surname>&#x00141;uksza</surname><given-names>M</given-names></name>, <name><surname>L&#x000e4;ssig</surname><given-names>M</given-names></name>. <article-title>A predictive fitness model for influenza</article-title>. <source>Nature</source>. <year>2014</year>;<volume>507</volume>: <fpage>57</fpage>&#x02013;<lpage>61</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nature13087">10.1038/nature13087</ext-link></comment>
<?supplied-pmid 24572367?><pub-id pub-id-type="pmid">24572367</pub-id></mixed-citation></ref><ref id="pcbi.1005838.ref016"><label>16</label><mixed-citation publication-type="journal">
<name><surname>Kucharski</surname><given-names>AJ</given-names></name>, <name><surname>Lessler</surname><given-names>J</given-names></name>, <name><surname>Read</surname><given-names>JM</given-names></name>, <name><surname>Zhu</surname><given-names>H</given-names></name>, <name><surname>Jiang</surname><given-names>CQ</given-names></name>, <name><surname>Guan</surname><given-names>Y</given-names></name>, <etal>et al</etal>
<article-title>Estimating the Life Course of Influenza A(H3N2) Antibody Responses from Cross-Sectional Data</article-title>. <source>PLoS Biol</source>. <year>2015</year>;<volume>13</volume>: <fpage>e1002082</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pbio.1002082">10.1371/journal.pbio.1002082</ext-link></comment>
<?supplied-pmid 25734701?><pub-id pub-id-type="pmid">25734701</pub-id></mixed-citation></ref><ref id="pcbi.1005838.ref017"><label>17</label><mixed-citation publication-type="journal">
<name><surname>Kucharski</surname><given-names>AJ</given-names></name>, <name><surname>Baguelin</surname><given-names>M</given-names></name>. <article-title>The role of human immunity and social behavior in shaping influenza evolution</article-title>. <source>PLOS Pathogens</source>. <year>2017</year>;<volume>13</volume>: <fpage>e1006432</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.ppat.1006432">10.1371/journal.ppat.1006432</ext-link></comment>
<?supplied-pmid 28771619?><pub-id pub-id-type="pmid">28771619</pub-id></mixed-citation></ref><ref id="pcbi.1005838.ref018"><label>18</label><mixed-citation publication-type="journal">
<name><surname>Hodgson</surname><given-names>D</given-names></name>, <name><surname>Baguelin</surname><given-names>M</given-names></name>, <name><surname>van Leeuwen</surname><given-names>E</given-names></name>, <name><surname>Panovska-Griffiths</surname><given-names>J</given-names></name>, <name><surname>Ramsay</surname><given-names>M</given-names></name>, <name><surname>Pebody</surname><given-names>R</given-names></name>, <etal>et al</etal>
<article-title>Effect of mass paediatric influenza vaccination on existing influenza vaccination programmes in England and Wales: A modelling and cost-effectiveness analysis</article-title>. <source>The Lancet Public Health</source>. <year>2017</year>;<volume>2</volume>: <fpage>e74</fpage>&#x02013;<lpage>e81</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S2468-2667(16)30044-5">10.1016/S2468-2667(16)30044-5</ext-link></comment>
<?supplied-pmid 28299371?><pub-id pub-id-type="pmid">28299371</pub-id></mixed-citation></ref><ref id="pcbi.1005838.ref019"><label>19</label><mixed-citation publication-type="journal">
<name><surname>Thorrington</surname><given-names>D</given-names></name>, <name><surname>van Leeuwen</surname><given-names>E</given-names></name>, <name><surname>Ramsay</surname><given-names>M</given-names></name>, <name><surname>Pebody</surname><given-names>R</given-names></name>, <name><surname>Baguelin</surname><given-names>M</given-names></name>. <article-title>Cost-effectiveness analysis of quadrivalent seasonal influenza vaccines in England</article-title>. <source>BMC Medicine</source>. <year>2017</year>;<volume>15</volume>: <fpage>166</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/s12916-017-0932-3">10.1186/s12916-017-0932-3</ext-link></comment>
<?supplied-pmid 28882149?><pub-id pub-id-type="pmid">28882149</pub-id></mixed-citation></ref></ref-list></back></article>